Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks
| Autor: | William Canovatchel, John Xie, Gary Meininger, Albert Fung, Kaj Stenlöf, Lawrence Blonde |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Waist 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology Gastroenterology Body Mass Index 03 medical and health sciences 0302 clinical medicine Weight loss Internal medicine Weight Loss medicine Humans Hypoglycemic Agents Canagliflozin Adiposity Aged Randomized Controlled Trials as Topic business.industry Body Weight Type 2 Diabetes Mellitus General Medicine Middle Aged medicine.disease Metformin Glimepiride Sulfonylurea Compounds Endocrinology Clinical Trials Phase III as Topic Diabetes Mellitus Type 2 Body Composition Female Waist Circumference medicine.symptom business Body mass index medicine.drug |
| Zdroj: | Postgraduate Medicine. 128:371-380 |
| ISSN: | 1941-9260 0032-5481 |
| Popis: | Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, has been associated with weight loss in a broad range of patients with type 2 diabetes mellitus (T2DM). This analysis further evaluated changes in body weight and composition with canagliflozin in two 104-week, Phase 3 studies.In Study 1, patients aged 18-80 years (N = 1,450) received canagliflozin 100 or 300 mg or glimepiride as add-on to metformin for a 52-week core treatment period, followed by a 52-week extension period. In Study 2, patients aged 55-80 years (N = 714) received canagliflozin 100 or 300 mg or placebo added to stable background antihyperglycemic agents for a 26-week core treatment period, followed by a 78-week extension period. Percent change from baseline in body weight; proportion of patients with any weight loss, ≥5% weight loss, and ≥10% weight loss; change in body mass index (BMI) and waist circumference; change in body weight across weight-loss quartiles; and changes in body composition were evaluated in both studies.Canagliflozin 100 and 300 mg provided sustained weight loss versus either glimepiride or placebo over 104 weeks. More patients experienced any weight loss and ≥5% weight loss with canagliflozin versus comparator. Across the 3 highest weight-loss quartiles, canagliflozin provided greater weight loss versus glimepiride or placebo. BMI and waist circumference reductions were observed with canagliflozin 100 and 300 mg versus either glimepiride or placebo over 104 weeks; more patients had BMI or waist circumference reductions with canagliflozin versus comparator. Body composition analysis indicated that the majority of weight loss was due to loss of fat mass. Canagliflozin was generally well tolerated, with increased incidence of adverse events related to the SGLT2 inhibition mechanism.Canagliflozin 100 and 300 mg provided sustained reductions in body weight, BMI, and waist circumference in a greater proportion of patients with T2DM versus glimepiride or placebo over 104 weeks.ClinicalTrials.gov NCT00968812, NCT01106651. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|